Success Metrics

Clinical Success Rate
90.0%

Based on 9 completed trials

Completion Rate
90%(9/10)
Active Trials
0(0%)
Results Posted
67%(6 trials)
Terminated
1(8%)

Phase Distribution

Ph not_applicable
2
15%
Ph phase_2
2
15%
Ph phase_4
3
23%
Ph phase_3
4
31%

Phase Distribution

0

Early Stage

2

Mid Stage

7

Late Stage

Phase Distribution11 total trials
Phase 2Efficacy & side effects
2(18.2%)
Phase 3Large-scale testing
4(36.4%)
Phase 4Post-market surveillance
3(27.3%)
N/ANon-phased studies
2(18.2%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

81.8%

9 of 11 finished

Non-Completion Rate

18.2%

2 ended early

Currently Active

0

trials recruiting

Total Trials

13

all time

Status Distribution
Completed(9)
Terminated(2)
Other(2)

Detailed Status

Completed9
unknown2
Terminated1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
13
Active
0
Success Rate
90.0%
Most Advanced
Phase 4

Trials by Phase

Phase 22 (18.2%)
Phase 34 (36.4%)
Phase 43 (27.3%)
N/A2 (18.2%)

Trials by Status

unknown215%
terminated18%
withdrawn18%
completed969%

Recent Activity

0 active trials
Showing 5 of 13
unknownnot_applicable

Azilsartan in Patients With Diabetic Kidney Disease and Hypertension

NCT05753696
terminatedphase_3

Host Response Mediators in Coronavirus (COVID-19) Infection - Is There a Protective Effect of Losartan and Other ARBs on Outcomes of Coronavirus Infection?

NCT04606563
completedphase_3

A Phase 3 Long-term Study of TAK-536 in Pediatric Patients 6 to Less Than 16 Years With Hypertension

NCT02791438
completed

Azilsaltan Tablets (Azilva Tablets) Special Drug Use Surveillance "Hypertension Complicated by Diabetes "

NCT02100319
completed

Azilsartan Tablets Special Drug Use Surveillance: Long-term Use

NCT02092025
View all 13 trials

Clinical Trials (13)

Showing 13 of 13 trials
NCT05753696Not Applicable

Azilsartan in Patients With Diabetic Kidney Disease and Hypertension

Unknown
NCT04606563Phase 3

Host Response Mediators in Coronavirus (COVID-19) Infection - Is There a Protective Effect of Losartan and Other ARBs on Outcomes of Coronavirus Infection?

Terminated
NCT02791438Phase 3

A Phase 3 Long-term Study of TAK-536 in Pediatric Patients 6 to Less Than 16 Years With Hypertension

Completed
NCT02100319

Azilsaltan Tablets (Azilva Tablets) Special Drug Use Surveillance "Hypertension Complicated by Diabetes "

Completed
NCT02092025

Azilsartan Tablets Special Drug Use Surveillance: Long-term Use

Completed
NCT02079805Phase 4

A Study to Explore the Effects of Azilsartan Compared to Telmisartan on Insulin Resistance of Patients With Essential Hypertension on Type 2 Diabetes Mellitus by HOMA-R

Completed
NCT02400775Phase 4

A Study to Evaluate the Effects of Azilsartan on Coronary Artery Plaque in Essential Hypertensive Patients With Stable Angina and Dyslipidemia.

Withdrawn
NCT02451150Phase 3

A Phase 3 Pharmacokinetic Study of TAK-536 (Azilsartan) in Pediatric Patients 6 to Less Than 16 Years With Hypertension

Completed
NCT01762501Not Applicable

Azilsartan Circadian and Sleep Pressure

Completed
NCT02407210Phase 3

Efficacy and Safety of Azilsartan Compared to Olmesartan Medoxomil in Chinese Participants With Grade I or II Essential Hypertension

Unknown
NCT01609959Phase 4

New Angiotensin II Receptor Blocker Azilsartan Study for Stronger Blood Pressure Lowering

Completed
NCT01289132Phase 2

Efficacy and Safety of Azilsartan in Participants With Mild to Moderate Uncomplicated Essential Hypertension

Completed
NCT00759551Phase 2

Efficacy and Safety of Azilsartan in Subjects With Essential Hypertension

Completed

All 13 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
13